The confluence of stereotactic ablative radiotherapy and tumor immunology

Steven Eric Finkelstein, Robert Timmerman, William H. McBride, Drthe Schaue, Sarah E. Hoffe, Constantine A. Mantz, George D. Wilson

Research output: Contribution to journalArticle

93 Scopus citations

Abstract

Stereotactic radiation approaches are gaining more popularity for the treatment of intracranial as well as extracranial tumors in organs such as the liver and lung. Technology, rather than biology, is driving the rapid adoption of stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), in the clinic due to advances in precise positioning and targeting. Dramatic improvements in tumor control have been demonstrated; however, our knowledge of normal tissue biology response mechanisms to large fraction sizes is lacking. Herein, we will discuss how SABR can induce cellular expression of MHC I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses.

Original languageEnglish (US)
Article number439752
JournalClinical and Developmental Immunology
Volume2011
DOIs
Publication statusPublished - 2011

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Finkelstein, S. E., Timmerman, R., McBride, W. H., Schaue, D., Hoffe, S. E., Mantz, C. A., & Wilson, G. D. (2011). The confluence of stereotactic ablative radiotherapy and tumor immunology. Clinical and Developmental Immunology, 2011, [439752]. https://doi.org/10.1155/2011/439752